Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals to acquire Coria Laboratories
Under the terms of the agreement, Valeant will purchase all of the outstanding shares of Coria from its parent company, DFB Pharmaceuticals, and other shareholders for $95 million,
Under the terms of the agreement, Valeant will purchase all of the outstanding shares of Coria from its parent company, DFB Pharmaceuticals, and other shareholders for $95 million,
Joseph Papa, chairman and CEO of Perrigo, said: “The acquisition of JB Laboratories will further expand our high-quality manufacturing base and provide additional FDA-approved production capacity to help
The Phase IIa randomized, placebo controlled clinical trial will evaluate the safety and immunogenicity of different doses of its seasonal influenza virus-like particle (VLP) vaccine. Specifically, the vaccine
The company completed its open-label, 24-week, multi-center study to assess the safety of oral glycopyrrolate liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients three to
The transaction is subject to customary conditions, including the tender of a majority of the outstanding shares of Datascope common stock into the tender offer, regulatory approvals and
In this role Ms Wolf will be responsible for all of Vision-Sciences’s financial operations and business development activities. Before joining Vision-Sciences, Ms Wolf was a managing director at
Most recently, Mr Paulson served as president and CEO of Restore Medical, where he led the company through the commercialization of its Pillar implant technology, its initial public
Pfizer has previously announced that it would stop marketing Exubera inhalation powder because it did not meet customers’ needs or Pfizer’s financial expectations. Since that time, Exubera patients
As a result, Epix will receive $500,000 from Cystic Fibrosis Foundation Therapeutics (CFFT), bringing the total amount of milestone payments achieved under this collaboration to $4.5 million. The
The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron’s GRNCM1 program is developing human embryonic stem cell (hESC)-derived